0.9643USD-4.52%Mkt Cap: 184.13M $P/E: —2d ago
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophage…
Industry Peers
Medical DevicesKey Statistics
Company
Market Cap184.13M $
Enterprise Value173.82M $
Revenue (TTM)5.45M $
Gross Profit-1.96M $
Net Income (TTM)-58.01M $
Revenue/Share0.0390 USD
Last Price0.9643 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees82
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.00
PEG—
EV/EBITDA-3.49
EV/Revenue31.92
P/S33.68
P/B16.85
EPS (TTM)-0.39
EPS (Forward)-0.16
52W Range
0.860514% of range1.629
52W High1.629 USD
52W Low0.8605 USD
Profitability
Gross Margin-41.73%
Oper. Margin-868.45%
EBITDA Margin0.00%
Profit Margin-1232.68%
ROE-530.45%
ROA-143.43%
Growth
Revenue Growth26.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-46.48M $
CapEx (TTM)197.00K $
FCF Margin-485.38%
FCF Yield-14.35%
Net Debt-9.56M $
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity2.36
Current Ratio1.33
Quick Ratio1.29
Book Value/Sh0.0570 USD
Cash/Share0.1810 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.950 USD
Upside (mean)+309.6%
Target Range2.000 USD – 9.250 USD
$2.000+309.6% to mean$9.250
# Analysts5
Ownership
Shares Out.190.95M
Float140.76M
Insiders26.50%
Institutions33.36%
Short Interest
Short Ratio8.1d
Short % Float7.87%
Short % Out.6.36%
Shares Short12.13M
Short (prev mo.)9.42M
Technical
SMA 500.9903 (-2.6%)
SMA 2001.120 (-13.9%)
Beta1.08
S&P 52W Chg18.16%
Avg Vol (30d)1.32M
Avg Vol (10d)881.65K
Technical Indicators
RSI (14)48.7
MACD-0.0019
MACD Signal-0.0086
MACD Hist.+0.0066
BB Upper1.022 USD
BB Middle0.9501 USD
BB Lower0.8782 USD
BB Width15.13%
ATR (14)0.0557 USD
Vol Ratio (20d)0.39x